Cytokinetics, Incorporated today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM.In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance with Cytokinetics’ global registration programs.

细胞动力学公司（Cytokinetics，Incorporated today）宣布，赛诺菲（Sanofi）将获得从Corxel Pharmaceuticals（Corxel）开发和商业化aficamten的专有权，用于治疗大中华地区的阻塞性和非阻塞性肥厚型心肌病（HCM）患者。Aficamten是下一类心肌肌球蛋白抑制剂，可用于HCM患者的潜在治疗。。

Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for aficamten tablets for the treatment of oHCM for Priority Review.Sanofi will now acquire CORXEL’s rights relating to aficamten in Greater China for an undisclosed amount.

Aficamten从药物评估中心获得了治疗症状性梗阻性肥厚型心肌病（oHCM）的突破性治疗指定 中国国家医药产品管理局最近接受了用于治疗oHCM的阿非卡姆汀片的新药申请，以进行优先审查。赛诺菲现在将以未披露的金额收购CORXEL在大中华区与aficamten相关的权利。

Cytokinetics remains eligible to receive up to $150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and CORXEL.“We have enjoyed a productive collaboration with CORXEL and appreciate all they have done to advance aficamten in Greater China,” said Robert I.

Cytokinetics仍有资格从赛诺菲获得高达1.5亿美元的开发和商业里程碑付款，以及未来在大中华区销售aficamten的低至高青少年的版税。Cytokinetics现在也有资格获得与赛诺菲和CORXEL之间协议执行相关的额外未披露付款。罗伯特一世（RobertI。

Blum, Cytokinetics’ President and CEO. “We now look forward to partnering with Sanofi with shared objective to leverage their cardiovascular expertise and expand the reach of aficamten to patien.

Blum，细胞动力学公司总裁兼首席执行官。“我们现在期待着与赛诺菲合作，以共同的目标利用他们的心血管专业知识，并将aficamten的影响力扩大到患者。